519 related articles for article (PubMed ID: 27479183)
1. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
2. HLA-DPB1 Reactive T Cell Receptors for Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation.
Klobuch S; Hammon K; Vatter-Leising S; Neidlinger E; Zwerger M; Wandel A; Neuber LM; Heilmeier B; Fichtner R; Mirbeth C; Herr W; Thomas S
Cells; 2020 May; 9(5):. PubMed ID: 32443793
[TBL] [Abstract][Full Text] [Related]
3. Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation.
Barakat C; Inagaki Y; Mizuno S; Nishio N; Katsuyama N; Sato Y; Kobayashi M; Ozeki K; Iida H; Tomita A; Sawa M; Demachi-Okamura A; Takahashi Y; Nishikawa H; Akatsuka Y
Int J Hematol; 2023 Aug; 118(2):252-266. PubMed ID: 37310580
[TBL] [Abstract][Full Text] [Related]
4. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
[TBL] [Abstract][Full Text] [Related]
5. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
6. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.
Rutten CE; van Luxemburg-Heijs SA; Griffioen M; Marijt EW; Jedema I; Heemskerk MH; Posthuma EF; Willemze R; Falkenburg JH
Leukemia; 2008 Jul; 22(7):1387-94. PubMed ID: 18418406
[TBL] [Abstract][Full Text] [Related]
7. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
8. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.
Rutten CE; van Luxemburg-Heijs SA; Halkes CJ; van Bergen CA; Marijt EW; Oudshoorn M; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jan; 19(1):40-8. PubMed ID: 22871556
[TBL] [Abstract][Full Text] [Related]
9. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
10. HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation.
Yabe T; Azuma F; Kashiwase K; Matsumoto K; Orihara T; Yabe H; Kato S; Kato K; Kai S; Mori T; Morishima S; Satake M; Takanashi M; Nakajima K; Morishima Y;
Leukemia; 2018 Jan; 32(1):168-175. PubMed ID: 28652579
[TBL] [Abstract][Full Text] [Related]
11. Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation.
Ibisch C; Gallot G; Vivien R; Diez E; Jotereau F; Garand R; Vié H
Bone Marrow Transplant; 1999 Jun; 23(11):1153-9. PubMed ID: 10382955
[TBL] [Abstract][Full Text] [Related]
12. Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation.
Meurer T; Arrieta-Bolaños E; Metzing M; Langer MM; van Balen P; Falkenburg JHF; Beelen DW; Horn PA; Fleischhauer K; Crivello P
Front Immunol; 2018; 9():2236. PubMed ID: 30344521
[TBL] [Abstract][Full Text] [Related]
13. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
Stevanovic S; van Bergen CA; van Luxemburg-Heijs SA; van der Zouwen B; Jordanova ES; Kruisselbrink AB; van de Meent M; Harskamp JC; Claas FH; Marijt EW; Zwaginga JJ; Halkes CJ; Jedema I; Griffioen M; Falkenburg JH
Blood; 2013 Sep; 122(11):1963-73. PubMed ID: 23777765
[TBL] [Abstract][Full Text] [Related]
14. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.
Pidala J; Lee SJ; Ahn KW; Spellman S; Wang HL; Aljurf M; Askar M; Dehn J; Fernandez Viña M; Gratwohl A; Gupta V; Hanna R; Horowitz MM; Hurley CK; Inamoto Y; Kassim AA; Nishihori T; Mueller C; Oudshoorn M; Petersdorf EW; Prasad V; Robinson J; Saber W; Schultz KR; Shaw B; Storek J; Wood WA; Woolfrey AE; Anasetti C
Blood; 2014 Oct; 124(16):2596-606. PubMed ID: 25161269
[TBL] [Abstract][Full Text] [Related]
15. T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.
Katsuyama N; Kawase T; Barakat C; Mizuno S; Tomita A; Ozeki K; Nishio N; Sato Y; Kajiya R; Shiraishi K; Takahashi Y; Ichinohe T; Nishikawa H; Akatsuka Y
Nagoya J Med Sci; 2023 Nov; 85(4):779-796. PubMed ID: 38155626
[TBL] [Abstract][Full Text] [Related]
16. The impact of amino acid variability on alloreactivity defines a functional distance predictive of permissive HLA-DPB1 mismatches in hematopoietic stem cell transplantation.
Crivello P; Zito L; Sizzano F; Zino E; Maiers M; Mulder A; Toffalori C; Naldini L; Ciceri F; Vago L; Fleischhauer K
Biol Blood Marrow Transplant; 2015 Feb; 21(2):233-41. PubMed ID: 25445022
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of major histocompatibility complex class I-related chain a and human leukocyte antigen-DPB1 mismatches in association with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation.
Askar M; Sun Y; Rybicki L; Zhang A; Thomas D; Kalaycio M; Pohlman B; Dean R; Duong H; Hanna R; Maciejewski J; Majhail NS; Bolwell B; Sobecks R
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1835-40. PubMed ID: 25064744
[TBL] [Abstract][Full Text] [Related]
18. Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells.
Distler E; Bloetz A; Albrecht J; Asdufan S; Hohberger A; Frey M; Schnürer E; Thomas S; Theobald M; Hartwig UF; Herr W
Haematologica; 2011 Jul; 96(7):1024-32. PubMed ID: 21486863
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant.
Moyer AM; Hashmi SK; Kroning CM; Kremers WK; De Goey SR; Patnaik M; Litzow M; Gastineau DA; Hogan WJ; Jacob EK; Kreuter JD; Wakefield LL; Gandhi MJ
Eur J Haematol; 2017 Sep; 99(3):275-282. PubMed ID: 28632323
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes.
Thomas-Kaskel AK; Portugal TG; Herchenbach D; Houet L; Veelken H; Finke J
Acta Haematol; 2007; 117(4):226-35. PubMed ID: 17308369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
